Zest Protocol is here to provide access to sustainable Bitcoin yield, for liquidity providers, through its lending pools. An on-chain Bitcoin capital market for institutional borrowers, Zest allows opportunities for on-chain financing, without the constant threat of liquidation. Bitcoin is not a passive asset, it needs productive action from its community to unlock its potential [...]

The post ​​Zest Protocol: Makes Passive Income With Bitcoin Easy appeared first on Blockonomi.

DBS announced that it is committing an additional SGD 100 million to the DBS Foundation which will expand its efforts in helping social enterprises and businesses-for-impact to grow. The funds

The post DBS Pledges Additional SGD 100 Million to Fund Social Enterprises appeared first on Fintech Singapore.

Ambient computing is a broad term that describes an environment of smart devices, data, AI decisions, and human activity that enables computer actions alongside everyday life, without the need for direct human commands or intervention. Ambient computing represents an unparalleled opportunity to enhance almost every sphere of society – from the professional to the personal. And in […]

The post Knowledge Graph Standards in Ambient Computing appeared first on DATAVERSITY.

We're playing a real-life game of Monopoly, where the rich get richer. The solution: a global cryptocurrency, with a built-in wealth tax.

The post Investor Mindset, Episode 12: The Hidden Laws of Money appeared first on Bitcoin Market Journal.

GensoKishi is the blockchain gaming iteration of the traditional videogame, Elemental Knights Online. The Rise of GameFi It is easy for those of us who follow the GameFi and Metaverse spaces closely to feel that we are late to the party. Axie Infinity’s AXS token has provided early investors with a roughly 4,000% return on […]

The post GensoKishi: A Blockchain Gaming Revolution appeared first on Coin Bureau.

Challenger commercial insurance broker hubb is using Horizon Workrooms on Meta Quest internally and externally

The post Insurance broker hubb reveals first-mover advantages to meeting in VR appeared first on VRWorldTech Magazine.

The post Report Casts Doubt on HoloLens 3, Microsoft Says AR Headset is “doing great” appeared first on Road to VR.

HONG KONG, Feb 10, 2022 - (ACN Newswire) - The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange").

Lepu Biopharma plans to offer 126,876,000H shares (subject to the Over-allotment Option), of which 114,188,000 H shares will be International Offer Shares (subject to reallocation and the Over-allotment Option), representing 90% of the initial offer shares; the remaining 12,688,000 H shares will be Hong Kong Offer Shares (subject to reallocation), representing 10% of the initial offer shares. Offer Price is between HK$6.87 and HK$7.38 per Offer H Share. Lepu Biopharma will open for Hong Kong Public Offering in Hong Kong at 9 a.m., 10 February 2022 (Thursday), and close at 12:00 noon, 15 February 2022 (Tuesday). Dealings in shares of Lepu Biopharma on the Main Board of the Hong Kong Stock Exchange is expected to commence on 23 February 2022 (Wednesday). The shares will be traded in board lot of 1,000 shares each. The Company's stock code is 2157.

-- China International Capital Corporation Hong Kong Securities Limited and Morgan Stanley Asia Limited are the Joint Sponsors and Joint Global Coordinators.

-- China International Capital Corporation Hong Kong Securities Limited, Morgan Stanley Asia Limited (exclusively for Hong Kong Offer Shares), Morgan Stanley & Co. International plc (exclusively for International Offer Shares), Haitong International Securities Company Limited, Huatai Financial Holdings (Hong Kong) Limited, China Galaxy International Securities (Hong Kong) Co., Limited and Valuable Capital Ltd. are the Joint Bookrunners.

-- China International Capital Corporation Hong Kong Securities Limited, Morgan Stanley Asia Limited (exclusively for Hong Kong Offer Shares), Morgan Stanley & Co. International plc (exclusively for International Offer Shares), Haitong International Securities Company Limited, Huatai Financial Holdings (Hong Kong) Limited, China Galaxy International Securities (Hong Kong) Co., Limited, Valuable Capital Ltd. and Tiger Brokers (HK) Global Limited (exclusively for International Offer Shares) are the Joint Lead Managers.

Lepu Biopharma was incorporated in 2018 and is a biopharmaceutical company focusing on oncology therapeutics. The Company has designed pipeline with a range of oncology products. As of the Latest Practicable Date, the Company had pipeline including eight clinical-stage drug candidates, three pre-clinical drug candidates and three clinical-stage combination therapies of the candidates in the pipeline. The product pipeline of Lepu Biopharma features broad-spectrum anti-tumor drugs, including primarily the anti-PD-1 antibody candidate, as the backbone, and a dual focus on ADC and oncolytic virus drug candidates, maximizing synergies in both drug efficacy and commercialization and enabling company to expand indications and addressable market. The Company takes Anti-PD-1 antibody candidate as the cornerstone of its immunotherapies, advances the research and development of related products. The Company filed an NDA of HX008 in melanoma in June 2021 with the NMPA, and filed an NDA of HX008 in MSI-H/dMMR solid tumors in October 2021 with the NMPA. In addition, the Company focus on the development of innovative drugs including ADC and oncolytic virus. According to Frost & Sullivan, the Company house the leading ADC drug candidate pipeline in China in terms of the number of clinical-stage ADC drug candidates. The comprehensive ADC and oncolytic virus pipeline of company creates synergies and maximizes its competitive strength in commercialization. As of the Latest Practicable Date, company had initiated 28 clinical trials, among which three had entered registration trial phase and two were ongoing in the U.S.

Core Product with Encouraging Clinical Trial Results and Advance R&D Smoothly

The major pipeline assets of Lepu Biopharma consist of four core products, namely, MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates.

Among core products, MRG003 and MRG002 are ADC drug candidates, MRG003 is the most advanced EGFR-targeted ADC in clinical-stage development in China and has the potential to seize market opportunities. The Company is conducting Phase II clinical trials of MRG003 in recurrent or metastatic advanced HNSCC, advanced NSCLC, BTC and NPC in China, and expects to initiate clinical trials in recurrent or metastatic advanced HNSCC in the U.S. and expand MRG003 indications based on the clinical data obtained, further expanding the overall addressable market with the aim of achieving international commercialization with MRG003.

MRG002 is an innovative HER2-targeted ADC. Company's pre-clinical studies revealed better efficacy as compared to T-DM1 (trastuzumab emtansine) in multiple Herceptin-resistant HER2 over- and low-expressing PDX models of the gastric cancer and breast cancer. The Company had initiated Phase II clinical trials of MRG002 in HER2 low-expressing and over-expressing breast cancer, UC (urothelial cancer) and HER2 over-expressing BTC. For HER2 over-expressing breast cancer, the Company had obtained approval from the NMPA of registration trial.

HX008 and LP002 are anti-PD-1/anti-PD-L1 drug candidates, HX008 is a humanized antagonist mAb to human PD-1, which demonstrated efficacy and a good safety profile in the completed Phase Ia clinical trial in solid tumors. As of the Latest Practicable Date, the Company was also in the process of conducting a Phase II clinical trial of HX008 in NMIBC and a Phase III clinical trial of HX008 in the second-line gastric cancer. LP002 is a humanized mAb against PD-L1, which has shown a favorable safety profile in a Phase Ia clinical study in advanced solid tumors. Lepu Biopharma are in the process of a cohort expansion trial in advanced digestive system cancer and have completed patient enrollment and entered the follow-up period for Phase II clinical trials in ES-SCLC in China.

Core Technology Platforms to Buttress Products

Lepu Biopharma has demonstrated capabilities in the development of innovative drugs spanning across early-stage molecular target identification and validation, pre-clinical development and CMC development. The Company has three synergistic core technology platforms around its pipeline specializing in ADC technology, antibody discovery and advanced process and analytical development.

The Company has fully integrated ADC technology platform covering discovery, process and analytical development and manufacturing, is able to design and create new molecules with innovative mechanisms and utilize cutting-edge technology, such as GlycoConnect(TM) site-specific conjugation technology. It has, among others, cutting-edge ADC technologies including sophisticated DAR control technology, advanced ADC conjugation technology, identification and validation of early-stage molecular targets, ADC process development and a well-established quality analysis system.

The Company has constructed a full human naive antibody library of 1011 scale, the platform reduces the reliance on animal immune systems to produce antibodies, and significantly shorten the development period of innovative drug candidates to four to six weeks compared to the traditional hybridoma technology. The Company has also constructed a trispecific antibody T cell engager platform by utilizing protein binding domains, such as nanobodies and scFv, to augment T cells' response to solid tumors.

Lepu Biophamra has an advanced process and analytical development platform for antibodies and ADCs. The Company has impl emented a comprehensive set of quality analysis methods and inspection technology to assess and control the product quality in the course of process and analytical development and production to fulfill the requirements for registration, in order to ensure a standardized process and analytical development and quality control.

Intellectual Property Promotes the Sustainable Development of Drugs
Implement Manufacturing and Commercialization Layout

Intellectual property is pivotal to the sustainable development and commercialization of drugs, the Company endeavors to ensure global full-life-cycle IP protection for drug candidates. As of the Latest Practicable Date, Company had 11 issued patents in China, 20 in the U.S., nine in Japan, seven in the European Union and one in each of South Korea, Australia, Chile, India, Colombia, Indonesia, New Zealand and Israel, and 74 pending patent applications, consisting of 15 in Mainland China and 59 in overseas jurisdictions such as the U.S., Japan, India, South Korea, Australia, Israel, and the European Union. Our patent portfolio spans across mAb structure, targeted epitope, CMC, usage, biopharmaceutical formulation and indications.

While Lepu Biopharma advancing its drug candidates, it has mapped out and is implementing the manufacturing and commercialization strategies. Company commenced the operation of a 2,000L GMP-compliant antibody production line in Beijing in 2019 in support of clinical trials for the antibody products, it is building a production line for oncolytic virus drugs in Beijing with a designed capacity of 200L, as well as a biologics manufacturing center in Shanghai Biotech Park, including production line with a designed capacity of 12,000L initially, coupled with laboratories and manufacturing facilities, and one production line with capacity of 6,000L under construction. The Company is building marketing forces in China and seeking partnership opportunities to support international expansion and commercialization.

Expedite Innovative Drugs Development
Advance Pipeline and Technology Platforms Construction

Lepu Biopharma strives to expedites immune checkpoint inhibitor therapy development, aims to achieve expedited and adequate market coverage of HX008 through both medical institutions and direct-to-patients distribution channels by leveraging the broad spectrum of indications covered by MSI-H/dMMR solid tumors. The Company expects to establish effective sales channels and strengthen the commercialization capabilities through the commercialization of HX008, which would also benefit its efforts to commercialize other drug candidates. The Company also plans to seek strategic partnerships with preeminent pharmaceutical companies internationally to maximize the clinical and commercial value of its immune checkpoint inhibitors.

Lepu Biopharma advances the clinical development of its candidates including ADC candidates, oncolytic virus candidates and combination therapies, plans to stay focused on the development of innovative products, create a pipeline for novel therapies, design and develop innovative products and build advanced technology platforms. In addition, the Company is committed to strengthening its overseas business development of pipeline, enhancing the brand awareness and continuously exploring the commercial value of its products and technology in the international market, and will make efforts to pursue out-licensing partnership opportunities in overseas markets. Furthermore, to meet the commercialization demand, the Company will expand GMP-compliant manufacturing facilities to increase capacity and enhance product quality.

The Founder, Chairman and Executive Director of Lepu Biopharma Co., Ltd. Dr. Pu Zhongjie said, "Since our inception, Lepu Biopharma focuses on the development of innovative drugs, the design and well-establishment of pipeline, we have established an integrated end-to-end platform across drug discovery, clinical development and CMC and GMP-compliant manufacturing. As an innovation-driven biopharmaceutical company leveraging an internationally integrated research and development system, we are committed to fulfilling current medical needs. Lepu Biopharma has solid R&D capabilities, advanced development platforms and comprehensive pipeline, we will the hold future trend and of the whole industry, use our competitive strengths to keep Lepu Biopharma's status in the market and maxmize the created value for shareholders and investors."



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comThe biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange").

New research finds that by 2026, 25% of everyone will spend at least one hour per day in the metaverse for work, shopping, education, social and/or entertainment. According to a new report from data insights firm Gartner, a burgeoning metaverse will develop with a fully operational virtual economy enabled by digital currencies and non-fungible tokens […]

The post A Quarter of All People Will Spend an Hour a Day In The Metaverse In Four Years appeared first on Coin Bureau.

A global philanthropic community is seeing rapid-fire growth across the world as members unite to bring about change in the world. The community was initiated by Philcoin – an award-winning philanthropic movement in the blockchain bridging the gap between philanthropy and technology. Philcoin was awarded Social Impact Project of the Year 2021 at AIBC in Malta.

Just days away from its official launch in February 2022, Philcoin's mission has spread further and faster than ever imagined. Philcoin's CEO, Jerry Lopez, said, “I am blown away by the community's support. We've been inundated with messages from around the world – from Asia to Latin America, Africa to Europe – from people who want to know how they can get involved. Our team is working around the clock, finalizing partnerships with incredible charities who share the same values we do, and our tech team is putting the finishing touches on our app that will connect the world to those in need.” 

Philcoin is the official cryptocurrency partner of the SDG Impact Fund and together they will be achieving the UN'S 17 Sustainable Development Goals. To explain the problems the partnership will be solving, Tony Suber, Executive Chairman of SDG Impact Fund says, “Imagine a humanitarian crisis happens in the world – a typhoon, drought, earthquake, pandemic or war – how would you be able to help from a different part of the world? There's no easy way to donate in an emergency, no single platform that exists for the sole purpose of helping those in need on a global scale and certainly not in the crypto space. This is the gap Philcoin and the SDG Impact Fund are looking to fill, together.”

The past two years have had a monumental impact on the world, its people and resources. With the pandemic slowly abating, we are seeing an escalation in natural disasters and fluke storms devastating communities around the world. Now, more than ever, people need a way to support the causes and charities they are most passionate about. They need a space where not only is it easy to give back, but the funds are able to reach those in need quickly and efficiently. Philcoin will provide a space on its website, app and social channels for people to donate at the click of a button.

Over the last few months, Philcoin has created a robust network through its social channels and app downloads. Join the movement today and visit linktree.com/philcoin

About Philcoin:

Philcoin is an award-winning philanthropic movement in the blockchain whose purpose is to establish a global interactive ecosystem where the daily use of IOT “Internet of Things” (social media, television, means of communication) become a rail where people can earn while they use the products and services. 

Given our history of humanitarian support and endeavors, Philcoin's purpose is to GIVE BACK while people transact in BLOCKCHAIN. 

Philcoin's vision is to create the largest community of philanthropists around the world in a time and age where over 1.7B people are unbanked, over 55% of people in the USA alone cannot read a book at an 8th grade level, and where giving back has been ignored as a global initiative in the blockchain space. A space where billions of dollars have been directed to projects without a purpose. 

Philcoin's mission is to help people build a digital economy while chatting, watching television, playing video games, getting educated and shopping. As well as using our philanthropic partnerships which allows everyone an equal opportunity in generating digital wealth, Philcoin uses Smart contracts which demonstrate a high level of a transparency, and a user-friendly environment, whilst fulfilling the purpose of the 17 SDGs and every humanitarian support in our ecosystem. 

For collaborations, partnerships & media enquiries, please contact:

Tatum April, Chief Marketing Officer

[email protected]

https://philcoin.io

PR CONTACT
Crypto World Seo
Pritam Chakraborty
Email:- [email protected]
Telegram :- cryptoworldseo

As a developer, it may be tempting to just start building features and products. However, before you take things to the keyboard, you should...

The crypto marketing company employs unique skills to ensure cryptocurrency projects are well-exposed for the world to experience. Furthermore, it ensures a strong relationship built on trust with all its clients while establishing more fruitful partnerships. More than anything, it aims at providing a clean slate for projects to develop trust with their users.

What Projects Can Expect from Crypto Virally

Crypto Virally is combining the best strategies available to make marketing a fulfilling experience. The crypto marketing agency leverages its resources to expand crypto project functionality from press releases to curating the best website copies.

According to a review by Bitrue crypto exchange, Crypto Virally has convenient services and a formidable team behind it. Its team aims to be the favorite crypto marketing agency, providing a push further in progressing crypto projects. 

One of the advantages of utilizing its services is increasing traffic to crypto websites. Moreover, it hopes to boost the social media presence of the projects through social media marketing steps.

Other services include Ask me anything (AMA) sessions, web design functions, creating extensive project awareness, and coming up and airing project content. 

You can count on expert dedication to provide you with excellent information on progressing your project. Furthermore, you have access to specialist advice and presence to ensure your marketing journey runs smoothly. One can depend on its security as it assures transparency, data security, and confidentiality as it carries out your marketing campaigns.

Versatility is Vital to Its Services

Every crypto service offers something different to its users. The same extends to what these platforms need when it comes to marketing. Crypto Virally is the bridge between crypto services, their users, and broadcasting the future of what they wish to present.

The crypto market is a growing industry with the potential to revolutionize the financial sector. There are over 13,000 coins in the industry today, with more coming in every day. This factor indicates the necessity of a good agency, versatile in knowledge and marketing options. Otherwise, the crypto market volatility and the competition would shatter the expectations you wish to get from crypto marketing.

Besides the broad array of services Crypto Virally has, it provides different payment options for its clients to increase convenience. The platform's blog contains extensive educational material to create more insights into digital crypto marketing.

It also expresses the extra costs most crypto companies expand in in-house crypto marketing. However, its services are an assured pathway for efficient marketing, more influential audiences at low costs. 

You can derive the best results for your crypto projects through dependable communication systems while delivering your objectives to trusted experts. Book a free consultation with Crypto Virally experts today for answers to all your crypto marketing questions.